| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8430100 | Biology of Blood and Marrow Transplantation | 2018 | 7 Pages |
Abstract
- Single dose of plerixafor on day 4 of PBSC harvest improves CD34+ HSC yield in the graft for poorly mobilizing haploidentical donors.
- Addition of plerixafor results in higher CD4+ T cells in the graft with similar yield of CD8+ T cells without any differential impact on mobilization of Tregs.
- NK cell mobilization is skewed toward CD56+/CD16â subset in both groups.
- Single-dose plerixafor is associated with self-limited mild gastrointestinal side effects in healthy donors with no serious adverse events.
- Plerixafor mobilized PBSC grafts do not affect short- or intermediate-term transplant outcomes for PTCy-based haploidentical HSCT in patients with malignant and nonmalignant diseases.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sarita Rani Jaiswal, Prakash Bhakuni, Aby Joy, Nisha Murli, Priyanka Bharadwaj, Shamsur Zaman, Murugayan Nedunchezian, Suparno Chakrabarti,